BIDFINDER

Special Notice · 36C25027Q0091

Q301 - Notice of Intent to Sole-Source Veracyte Decipher Testing Services - Cleveland OH VAMC

Department of Veterans Affairs · Ohio

This is a notice (Special Notice), not a request for offers.

Agency
Department of Veterans Affairs Federal250-NETWORK Contract Office 10 (36C250)
Place
Ohio
Offers due
November 12, 2026, 4:00 PM (ET) closes in 3 days
Estimated value
not stated
Notice type
Special Notice
Category
Medical and pharmaceutical
NAICS code
334516 Analytical Laboratory Instrument Manufacturing
Product service code (PSC)
Q301
Posted
November 4, 2026
Solicitation number
36C25027Q0091
Open the official notice

Opens the notice on SAM.gov, with its attachments and how to respond.

New bids by email: Medical and pharmaceutical in Ohio

At most one email a day, only when there are new bids. You confirm by email and can unsubscribe in one click. Privacy

Source: SAM.gov Contract Opportunities, the U.S. government's official list of federal contract opportunities.

Description

Notice of Intent to Sole-Source Requirement The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The associated NAICS code for this is 334516, Size Standard is 1,000 employees. Product Service Code (PSC) is Q301. The sole-source contract will be awarded to: VERACYTE, INC UEI: JS7GBP6LCMN6 Description of equipment requirements: The VA Northeast Ohio Healthcare System (VANEOHS) requires continued access to specialized genomic classifier testing used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer. Decipher prostate testing is a powerful diagnostic and prognostic tool that assesses risk of prostate cancer progression within the next five years post detection, biopsy or surgical removal. The test utilizes a genome-wide transcriptome assay to analyze the expression of 22 genes to generate the Decipher score. Performed on existing tissue samples obtained during biopsy or surgical removal of the prostate, prior to any radiation or hormone therapy. Indicated in localized, N1, or metastatic disease. Provides the Decipher score based on genomic characteristics of the tumor, independent of clinical and pathological factors. The score, ranging between 0 and 1, reflects tumor aggressiveness. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy: [email removed] & Samantha Jarrett: [email removed] by 4:00 p.m. EST November 12th, 2026.

Browse more bids

More open bids from this agency

Similar open bids